Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2019 Aug 26. pii: AAC.00959-19. doi: 10.1128/AAC.00959-19. [Epub ahead of print]

In vitro Activity of Rifampin, Rifabutin, Rifapentine and Rifaximin Against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection.

Author information

1
Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
2
Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN.
3
Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN.
4
Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN patel.robin@mayo.edu.

Abstract

in vitro activities of rifampin, rifabutin, rifapentine and rifaximin were tested against 200 PJI-associated staphylococci. Seven rifampin-resistant isolates had MICs ≥4 μg/mL. Three isolates had rifampin MICs 0.25-1μg/mL and harbored a Asp471Gly RpoB variant. The remaining isolates had rifampin MICs ≤0.016 μg/mL. Rifampin, rifabutin, rifapentine and rifaximin MBBC50 values for rifampin-susceptible isolates were 8, 1, 2, 4 (S. aureus), and 2, 0.06, 0.25, 0.5 (S. epidermidis) μg/mL, respectively. Non-rifampin rifamycins have promising staphylococcal anti-biofilm activity.

PMID:
31451499
DOI:
10.1128/AAC.00959-19

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center